Enterococcus faecium

Last updated

Enterococcus faecium
Scientific classification OOjs UI icon edit-ltr.svg
Domain: Bacteria
Phylum: Bacillota
Class: Bacilli
Order: Lactobacillales
Family: Enterococcaceae
Genus: Enterococcus
Species:
E. faecium
Binomial name
Enterococcus faecium
(Orla-Jensen 1919)
Schleifer & Kilpper-Bälz 1984

Enterococcus faecium is a Gram-positive, gamma-hemolytic or non-hemolytic bacterium in the genus Enterococcus . [1] It can be commensal (innocuous, coexisting organism) in the gastrointestinal tract of humans and animals, [2] but it may also be pathogenic, causing diseases such as neonatal meningitis or endocarditis.

Contents

Vancomycin-resistant E. faecium is often referred to as VRE. [3]

Pathogenic properties

This bacterium has developed multi-drug antibiotic resistance and uses colonization and secreted factors in virulence (enzymes capable of breaking down fibrin, protein and carbohydrates to regulate adherence bacteria to inhibit competitive bacteria). The enterococcal surface protein (Esp) allows the bacteria to aggregate and form biofilms. Additional virulence factors include aggregation substance (AS), cytosolin, and gelantinase. AS allows the microbe to bind to target cells and it facilitates the transfer of genetic material between cells. [4]

By producing the enterocins A, B, and P (genus-specific bacteriocins), Enterococcus faecium can combat pathogenic gut microbes, such as Escherichia coli, reducing gastrointestinal disease in hosts. [5] [6] As an alternative to adding antibiotics to livestock feed, which risks antimicrobial resistance, E. faecium Strain NCIMB 10415 is being used as a probiotic in animal feed. [7] However, the constant exposure to high levels of this microbe result in immunosuppression by reducing expression of IL-8, IL-10, and CD86, predisposing livestock to severe Salmonella infections. [8]

Vancomycin-resistant Enterococci (VRE)

Enterococcus faecium has been a leading cause of multi-drug resistant enterococcal infections over Enterococcus faecalis in the United States. Approximately 40% of medical intensive care units reportedly found that the majority, respectively 80% and 90.4%, of device-associated infections (namely, infections due to central lines, urinary drainage catheters, and ventilators) were due to vancomycin- and ampicillin-resistant E. faecium. [9]

The rapid increase of VRE has made it difficult for physicians to fight infections caused by E. faecium since not many antimicrobial solutions are available. In the United States infections by VRE occurs more frequently. [2]

Persons infected or colonized with VRE are more likely to transmit the organism. Transmission depends primarily on which body site(s) harbor the bacteria, whether the body fluids are excreted and how frequently health care providers touch these body sites. Patients infected or colonized with VRE may be cared for in any patient care setting with minimal risk of transmission to other patients provided appropriate infection control measures are taken. [10]

A genome-wide E. faecium sRNA study suggested that some sRNAs are linked to the antibiotic resistance and stress response. [11]

VRE symptoms

Enterococcus infections, including VRE infections, cause a range of different symptoms depending on the location of the infection. This includes infections of the bloodstream, urinary tract infections (UTI), and wound infections associated with catheters or surgery. Wound infections associated with catheters and surgery can cause soreness and swelling at wound site, red, warm skin around wounds, and fluid leakage. Urinary tract infections can cause frequent or intense urges to urinate, pain or burning sensations while urinating, fatigue, and lower back or abdominal pain. Bloodstream infections can cause fever, chills, body aches, nausea and vomiting, and diarrhea. [12]

Tolerance to alcohol-based disinfectants

A study published in 2018 showed multi drug-resistant E. faecium exhibiting tolerance to alcohol-based solutions. The authors speculated about this being an explanation to an increase of E. faecium infections, indicating that alternate methods are required to slow the spread of E. faecium in a hospital setting. The study found that isolates of the bacterium from after 2010 were 10 times more tolerant of the alcohol-based disinfectants than older isolates. However, the isopropanol solutions tested in this study used isopropanol concentrations lower than those used in most hand disinfectants and the authors also stated that hand disinfectants using 70% isopropanol were effective in full strength even against tolerant strains. [13] However, a mouse gut colonization model of E. faecium transmission showed that alcohol-tolerant E. faecium resisted standard 70% isopropanol surface disinfection, resulting in greater mouse gut colonization compared to alcohol-sensitive E. faecium. This research has led some to question whether it may be possible for microbes to become entirely tolerant of alcohol. [14]

Treatment

Linezolid, daptomycin, tigecycline [15] and the streptogramins (e.g. quinupristin/dalfopristin) can have activity against VRE. VRE can be successfully treated with sultamicillin. [16]

Related Research Articles

<span class="mw-page-title-main">Vancomycin</span> Antibiotic medication

Vancomycin is a glycopeptide antibiotic medication used to treat a number of bacterial infections. It is used intravenously as a treatment for complicated skin infections, bloodstream infections, endocarditis, bone and joint infections, and meningitis caused by methicillin-resistant Staphylococcus aureus. Blood levels may be measured to determine the correct dose. Vancomycin is also taken orally as a treatment for severe Clostridium difficile colitis. When taken orally it is poorly absorbed.

<i>Enterococcus</i> Genus of bacteria

Enterococcus is a large genus of lactic acid bacteria of the phylum Bacillota. Enterococci are gram-positive cocci that often occur in pairs (diplococci) or short chains, and are difficult to distinguish from streptococci on physical characteristics alone. Two species are common commensal organisms in the intestines of humans: E. faecalis (90–95%) and E. faecium (5–10%). Rare clusters of infections occur with other species, including E. casseliflavus, E. gallinarum, and E. raffinosus.

<span class="mw-page-title-main">Linezolid</span> Antibiotic medication

Linezolid is an antibiotic used for the treatment of infections caused by Gram-positive bacteria that are resistant to other antibiotics. Linezolid is active against most Gram-positive bacteria that cause disease, including streptococci, vancomycin-resistant enterococci (VRE), and methicillin-resistant Staphylococcus aureus (MRSA). The main uses are infections of the skin and pneumonia although it may be used for a variety of other infections including drug-resistant tuberculosis. It is used either by injection into a vein or by mouth.

<span class="mw-page-title-main">Hospital-acquired infection</span> Infection that is acquired in a hospital or other health care facility

A hospital-acquired infection, also known as a nosocomial infection, is an infection that is acquired in a hospital or other healthcare facility. To emphasize both hospital and nonhospital settings, it is sometimes instead called a healthcare-associated infection. Such an infection can be acquired in a hospital, nursing home, rehabilitation facility, outpatient clinic, diagnostic laboratory or other clinical settings. A number of dynamic processes can bring contamination into operating rooms and other areas within nosocomial settings. Infection is spread to the susceptible patient in the clinical setting by various means. Healthcare staff also spread infection, in addition to contaminated equipment, bed linens, or air droplets. The infection can originate from the outside environment, another infected patient, staff that may be infected, or in some cases, the source of the infection cannot be determined. In some cases the microorganism originates from the patient's own skin microbiota, becoming opportunistic after surgery or other procedures that compromise the protective skin barrier. Though the patient may have contracted the infection from their own skin, the infection is still considered nosocomial since it develops in the health care setting. Nosocomial infection tends to lack evidence that it was present when the patient entered the healthcare setting, thus meaning it was acquired post-admission.

Vancomycin-resistant <i>Staphylococcus aureus</i> Antibiotica resistant bacteria

Vancomycin-resistant Staphylococcus aureus (VRSA) are strains of Staphylococcus aureus that have acquired resistance to the glycopeptide antibiotic vancomycin. Bacteria can acquire resistant genes either by random mutation or through the transfer of DNA from one bacterium to another. Resistance genes interfere with the normal antibiotic function and allow a bacteria to grow in the presence of the antibiotic. Resistance in VRSA is conferred by the plasmid-mediated vanA gene and operon. Although VRSA infections are uncommon, VRSA is often resistant to other types of antibiotics and a potential threat to public health because treatment options are limited. VRSA is resistant to many of the standard drugs used to treat S. aureus infections. Furthermore, resistance can be transferred from one bacterium to another.

Multiple drug resistance (MDR), multidrug resistance or multiresistance is antimicrobial resistance shown by a species of microorganism to at least one antimicrobial drug in three or more antimicrobial categories. Antimicrobial categories are classifications of antimicrobial agents based on their mode of action and specific to target organisms. The MDR types most threatening to public health are MDR bacteria that resist multiple antibiotics; other types include MDR viruses, parasites.

Vancomycin-resistant <i>Enterococcus</i> Bacterial strains of Enterococcus that are resistant to the antibiotic vancomycin

Vancomycin-resistant Enterococcus, or vancomycin-resistant enterococci (VRE), are bacterial strains of the genus Enterococcus that are resistant to the antibiotic vancomycin.

<i>Enterococcus faecalis</i> Species of bacterium

Enterococcus faecalis – formerly classified as part of the group D Streptococcus system – is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans. Like other species in the genus Enterococcus, E. faecalis is found in healthy humans and can be used as a probiotic. The probiotic strains such as Symbioflor1 and EF-2001 are characterized by the lack of specific genes related to drug resistance and pathogenesis. As an opportunistic pathogen, E. faecalis can cause life-threatening infections, especially in the nosocomial (hospital) environment, where the naturally high levels of antibiotic resistance found in E. faecalis contribute to its pathogenicity. E. faecalis has been frequently found in reinfected, root canal-treated teeth in prevalence values ranging from 30% to 90% of the cases. Re-infected root canal-treated teeth are about nine times more likely to harbor E. faecalis than cases of primary infections.

<span class="mw-page-title-main">Dalfopristin</span> Chemical compound

Dalfopristin is a semi-synthetic streptogramin antibiotic analogue of ostreogyrcin A. The combination quinupristin/dalfopristin was brought to the market by Rhone-Poulenc Rorer Pharmaceuticals in 1999. Synercid is used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium.

<span class="mw-page-title-main">Oritavancin</span> Pharmaceutical drug

Oritavancin, sold under the brand name Orbactiv among others, is a semisynthetic glycopeptide antibiotic medication for the treatment of serious Gram-positive bacterial infections. Its chemical structure as a lipoglycopeptide is similar to vancomycin.

Streptogramins are a class of antibiotics.

Enterococcus gallinarum is a species of Enterococcus. E. gallinarum demonstrates an inherent, low-level resistance to vancomycin. Resistance is due to a chromosomal gene, vanC, which encodes for a terminal D-alanine-D-serine instead of the usual D-alanine-D-alanine in cell wall peptidoglycan precursor proteins. That is a separate mechanism than the vancomycin resistance seen in VRE isolates of E. faecium and E. faecalis which is mediated by vanA or vanB. This species is known to cause clusters of infection, although it considered very rare. It is the only other known enterococcal species besides E. faecium and E. faecalis known to cause outbreaks and spread in hospitals.

Enterococcus malodoratus is a species of the genus Enterococcus and a gram positive bacteria capable of opportunistic pathogenic response. These microbes have a thick polypeptide layer. Enterococcus can be found in the gastrointestinal tracts of humans and other mammals. In a study on the enterococcal flora of swine, E. malodoratus was found in the intestines and feces. It was not identified within the tonsils of swine, nor within cats, calves, dogs, horse, or poultry. The name "malodoratus" translates to "ill smelling".

Enterococcus raffinosus is a bacterial species of the Gram-positive genus Enterococcus, named for its facultative anaerobic metabolism, including the ability to ferment the trisaccharide raffinose. This mesophilic microaerophile has optimal growth at 37°C in Columbia Blood Medium. It has an ovoid morphology categorized as coccal with arrangement singly, in pairs, or short chains.

<i>Clostridioides difficile</i> Species of bacteria

Clostridioides difficile is a bacterium known for causing serious diarrheal infections, and may also cause colon cancer. It is known also as C. difficile, or C. diff, and is a Gram-positive species of spore-forming bacteria. Clostridioides spp. are anaerobic, motile bacteria, ubiquitous in nature and especially prevalent in soil. Its vegetative cells are rod-shaped, pleomorphic, and occur in pairs or short chains. Under the microscope, they appear as long, irregular cells with a bulge at their terminal ends. Under Gram staining, C. difficile cells are Gram-positive and show optimum growth on blood agar at human body temperatures in the absence of oxygen. C. difficile is catalase- and superoxide dismutase-negative, and produces up to three types of toxins: enterotoxin A, cytotoxin B and Clostridioides difficile transferase. Under stress conditions, the bacteria produce spores that are able to tolerate extreme conditions that the active bacteria cannot tolerate.

ESKAPE is an acronym comprising the scientific names of six highly virulent and antibiotic resistant bacterial pathogens including: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp. The acronym is sometimes extended to ESKAPEE to include Escherichia coli. This group of Gram-positive and Gram-negative bacteria can evade or 'escape' commonly used antibiotics due to their increasing multi-drug resistance (MDR). As a result, throughout the world, they are the major cause of life-threatening nosocomial or hospital-acquired infections in immunocompromised and critically ill patients who are most at risk. P. aeruginosa and S. aureus are some of the most ubiquitous pathogens in biofilms found in healthcare. P. aeruginosa is a Gram-negative, rod-shaped bacterium, commonly found in the gut flora, soil, and water that can be spread directly or indirectly to patients in healthcare settings. The pathogen can also be spread in other locations through contamination, including surfaces, equipment, and hands. The opportunistic pathogen can cause hospitalized patients to have infections in the lungs, blood, urinary tract, and in other body regions after surgery. S. aureus is a Gram-positive, cocci-shaped bacterium, residing in the environment and on the skin and nose of many healthy individuals. The bacterium can cause skin and bone infections, pneumonia, and other types of potentially serious infections if it enters the body. S. aureus has also gained resistance to many antibiotic treatments, making healing difficult. Because of natural and unnatural selective pressures and factors, antibiotic resistance in bacteria usually emerges through genetic mutation or acquires antibiotic-resistant genes (ARGs) through horizontal gene transfer - a genetic exchange process by which antibiotic resistance can spread.

Kerry L. LaPlante is an American pharmacist, academic and researcher. She is the Dean at the University of Rhode Island College of Pharmacy. She is a Professor of Pharmacy and former department Chair of the Department of Pharmacy Practice at the University of Rhode Island, an Adjunct Professor of Medicine at Brown University, an Infectious Diseases Pharmacotherapy Specialist, and the Director of the Rhode Island Infectious Diseases Fellowship and Research Programs at the Veterans Affairs Medical Center in Providence, Rhode Island.

<span class="mw-page-title-main">Antimicrobial nanotechnology</span>

Antimicrobial nanotechnology is the study of using biofilms to disrupt a microbe's cell membrane, deliver an electric charge to the microbe, and cause immediate cellular death via a "mechanical kill" process, preventing the original microbe from mutating into a superbug.

References

  1. Ryan KJ, Ray CG, Sherris JC (2004). Sherris Medical Microbiology (4th ed.). McGraw Hill. pp. 294–5. ISBN   0-8385-8529-9.
  2. 1 2 Willem RJ. "Emerging Infectious Diseases". Centers for Disease Control and Prevention. Retrieved 23 October 2017.
  3. Mascini EM, Troelstra A, Beitsma M, Blok HE, Jalink KP, Hopmans TE, et al. (March 2006). "Genotyping and preemptive isolation to control an outbreak of vancomycin-resistant Enterococcus faecium". Clinical Infectious Diseases. 42 (6): 739–746. doi: 10.1086/500322 . PMID   16477546.
  4. Agudelo Higuita NI, Huycke MM (2014). "Enterococcal Disease, Epidemiology, and Implications for Treatment". In Gilmore MS, Clewell DB, Ike Y, Yasuyoshi S, Shankar N (eds.). Enterococci: From Commensals to Leading Causes of Drug Resistant Infection. Boston: Massachusetts Eye and Ear Infirmary. PMID   24649504.
  5. Zommiti M, Cambronel M, Maillot O, Barreau M, Sebei K, Feuilloley M, et al. (2018). "Evaluation of Probiotic Properties and Safety of Enterococcus faecium Isolated From Artisanal Tunisian Meat "Dried Ossban"". Frontiers in Microbiology. 9: 1685. doi: 10.3389/fmicb.2018.01685 . PMC   6088202 . PMID   30127770.
  6. Hanchi H, Mottawea W, Sebei K, Hammami R (2018). "The Genus Enterococcus: Between Probiotic Potential and Safety Concerns-An Update". Frontiers in Microbiology. 9: 1791. doi: 10.3389/fmicb.2018.01791 . PMC   6085487 . PMID   30123208.
  7. Bednorz C, Guenther S, Oelgeschläger K, Kinnemann B, Pieper R, Hartmann S, et al. (December 2013). "Feeding the probiotic Enterococcus faecium strain NCIMB 10415 to piglets specifically reduces the number of Escherichia coli pathotypes that adhere to the gut mucosa". Applied and Environmental Microbiology. 79 (24): 7896–7904. doi:10.1128/AEM.03138-13. PMC   3837809 . PMID   24123741.
  8. Siepert B, Reinhardt N, Kreuzer S, Bondzio A, Twardziok S, Brockmann G, et al. (January 2014). "Enterococcus faecium NCIMB 10415 supplementation affects intestinal immune-associated gene expression in post-weaning piglets". Veterinary Immunology and Immunopathology. 157 (1–2): 65–77. doi:10.1016/j.vetimm.2013.10.013. PMID   24246154.
  9. Gilmore MS, Clewell DB, Ike Y, Shankar N, Agudelo Higuita NI, Huycke MM (February 2014). "Enterococcal Disease, Epidemiology, and Implications for Treatment". In Gilmore MS, Clewell DB, Ike Y (eds.). Enterococci: From Commensals to Leading Causes of Drug Resistant Infection. Massachusetts Eye and Ear Infirmary. PMID   24649504.
  10. "Enterococcal Infections, Vancomycin Resistant" (PDF). Infectious Disease Epidemiology Section Office of Public Health, Louisiana Dept of Health & Hospitals. 8 September 2008.
  11. Sinel C, Augagneur Y, Sassi M, Bronsard J, Cacaci M, Guérin F, et al. (September 2017). "Small RNAs in vancomycin-resistant Enterococcus faecium involved in daptomycin response and resistance". Scientific Reports. 7 (1): 11067. Bibcode:2017NatSR...711067S. doi:10.1038/s41598-017-11265-2. PMC   5593968 . PMID   28894187.
  12. "VRE in Healthcare Settings". United States Centers for Disease Control. Retrieved 23 May 2017.
  13. Pidot SJ, Gao W, Buultjens AH, Monk IR, Guerillot R, Carter GP, et al. (August 2018). "Increasing tolerance of hospital Enterococcus faecium to handwash alcohols". Science Translational Medicine. 10 (452): eaar6115. doi: 10.1126/scitranslmed.aar6115 . PMID   30068573.
  14. "Some Bacteria Are Becoming 'More Tolerant' Of Hand Sanitizers, Study Finds". NPR.org. Retrieved 2018-08-06.
  15. Cai Y, Wang R, Liang B, Bai N, Liu Y (March 2011). "Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease". Antimicrobial Agents and Chemotherapy. 55 (3): 1162–1172. doi:10.1128/AAC.01402-10. PMC   3067123 . PMID   21173186.
  16. Chewning JH (July 2011). "Vancomycin-resistant Enterococcus faecium bacteremia successfully treated with high-dose ampicillin-sulbactam in a pediatric patient after hematopoietic stem cell transplantation". Journal of Pediatric Hematology/Oncology. 33 (5): 401. doi:10.1097/MPH.0b013e31820db7eb. PMID   21602724.

Further reading